Global Cell Therapy Biomanufacturing Market Size study, by Product Type, by Cell Type, by Process, by End User, and Regional Forecasts 2022-2032

Description

The global market for Cell Therapy Biomanufacturing is valued at approximately USD 8.70 billion in 2023 and is expected to grow at a healthy compound annual growth rate (CAGR) of 11.5% during the forecast period 2024-2032, reaching an estimated USD 23.17 billion by 2032. Cell therapy biomanufacturing is an intricate process that involves the production, expansion, and modification of living cells for therapeutic applications. These processes are pivotal for developing treatments aimed at repairing or replacing damaged tissues, regenerating organs, or enhancing the immune system to combat diseases. The applications of these therapies are diverse, encompassing areas such as cancer immunotherapy with CAR-T cells, regenerative medicine through stem cell therapies, and the treatment of genetic disorders. The increasing prevalence of chronic diseases globally and the relentless advancements in biotechnology are driving the demand for cell therapy biomanufacturing. Furthermore, the surge in government and private sector investments is bolstering the development and scalability of these therapies, making personalized and advanced treatments more accessible.

The market's growth is underpinned by the rising incidence of chronic diseases, such as cancer, cardiovascular disorders, and autoimmune conditions. Cell therapies, which involve modifying or engineering cells to treat or cure diseases, are emerging as promising solutions for conditions that are difficult to manage with conventional treatments. As the burden of these diseases escalates globally, there is a corresponding increase in demand for innovative therapeutic solutions, leading to a significant rise in cell therapy biomanufacturing activities. Moreover, advancements in biotechnology, particularly in gene editing and stem cell research, are revolutionizing the cell therapy landscape. Techniques like CRISPR-Cas9 have enabled precise genetic modifications, enhancing the effectiveness of cell therapies. Additionally, improvements in biomanufacturing processes, including automation and bioprocessing technologies, are driving efficiency and scalability in cell therapy production, helping meet the growing demand.

The global cell therapy biomanufacturing market is poised for substantial growth due to various opportunities, including the shift towards personalized medicine. Personalized cell therapies, tailored to individual genetic profiles, promise more effective treatment outcomes, thereby driving the need for advanced biomanufacturing capabilities. Additionally, emerging markets present significant opportunities for growth, as these regions are rapidly adopting advanced medical technologies and expanding healthcare infrastructure. However, the market faces challenges, particularly the high costs associated with manufacturing cell therapies. The complex and labor-intensive processes involved, along with the need for specialized equipment and facilities, contribute to the high expenses, potentially limiting accessibility and widespread adoption. Addressing these cost challenges while maintaining quality and efficacy will be critical for the long-term success of the market.

The key regions considered for the global Cell Therapy Biomanufacturing market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in 2023, driven by robust research and development activities, a well-established healthcare infrastructure, and significant government and private sector investments in biotechnology. Europe also holds a substantial market share, with growing adoption of advanced therapies and supportive regulatory frameworks. The Asia Pacific region is anticipated to witness the fastest growth during the forecast period, propelled by increasing investments in healthcare infrastructure, rising demand for advanced medical treatments, and the growing prevalence of chronic diseases.

Major market players included in this report are:

MaxCyte (US)
Thermo Fisher Scientific Inc. (US)
L7 Informatics, Inc. (US)
MAK-SYSTEM (US)
SIRION Biotech GmbH (Germany)
Fresenius Medical Care AG & Co. KGaA (Germany)
Sartorius AG (Germany)
STEMCELL Technologies (Canada)
Werum IT Solutions GmbH (Germany)
Terumo BCT (US)
Corning Incorporated (US)
OrganaBio, LLC (US)
Merck KGaA (Germany)
Becton, Dickinson and Company (US)
Miltenyi Biotec GmbH (Germany)

The detailed segments and sub-segment of the market are explained below:

By Product Type:

Consumables
Equipment
Systems & Software

By Cell Type:

T-cell
Stem Cell
Other Cell

By Process:

Cell Processing
Cell Preservation, Distribution, and Handling
Process Monitoring and Quality Control

By End User:

Biopharmaceutical & Biotechnology Companies and CROs
Research Institutes and Cell Banks

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand-side and supply-side analysis of the market.

Chapter 1. Global Cell Therapy Biomanufacturing Market Executive Summary

1.1. Global Cell Therapy Biomanufacturing Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Product Type
- 1.3.2. By Cell Type
- 1.3.3. By Process
- 1.3.4. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Cell Therapy Biomanufacturing Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Cell Therapy Biomanufacturing Market Dynamics

3.1. Market Drivers
- 3.1.1. Increasing Prevalence of Chronic Diseases
- 3.1.2. Advancements in Biotechnology
- 3.1.3. Government and Private Sector Investments
3.2. Market Challenges
- 3.2.1. High Manufacturing Costs
3.3. Market Opportunities
- 3.3.1. Personalized Medicine
- 3.3.2. Expansion in Emerging Markets

Chapter 4. Global Cell Therapy Biomanufacturing Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Cell Therapy Biomanufacturing Market Size & Forecasts by Product Type 2022-2032

5.1. Segment Dashboard
5.2. Global Cell Therapy Biomanufacturing Market: Product Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Consumables
- 5.2.2. Equipment
- 5.2.3. Systems & Software

Chapter 6. Global Cell Therapy Biomanufacturing Market Size & Forecasts by Cell Type 2022-2032

6.1. Segment Dashboard
6.2. Global Cell Therapy Biomanufacturing Market: Cell Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. T-cell
- 6.2.2. Stem Cell
- 6.2.3. Other Cell

Chapter 7. Global Cell Therapy Biomanufacturing Market Size & Forecasts by Process 2022-2032

7.1. Segment Dashboard
7.2. Global Cell Therapy Biomanufacturing Market: Process Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Cell Processing
- 7.2.2. Cell Preservation, Distribution, and Handling
- 7.2.3. Process Monitoring and Quality Control

Chapter 8. Global Cell Therapy Biomanufacturing Market Size & Forecasts by End User 2022-2032

8.1. Segment Dashboard
8.2. Global Cell Therapy Biomanufacturing Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Biopharmaceutical & Biotechnology Companies and CROs
- 8.2.2. Research Institutes and Cell Banks

Chapter 9. Global Cell Therapy Biomanufacturing Market Size & Forecasts by Region 2022-2032

9.1. North America Cell Therapy Biomanufacturing Market
- 9.1.1. U.S. Cell Therapy Biomanufacturing Market
  - 9.1.1.1. Product Type breakdown size & forecasts, 2022-2032
  - 9.1.1.2. Cell Type breakdown size & forecasts, 2022-2032
  - 9.1.1.3. Process breakdown size & forecasts, 2022-2032
  - 9.1.1.4. End User breakdown size & forecasts, 2022-2032
- 9.1.2. Canada Cell Therapy Biomanufacturing Market
9.2. Europe Cell Therapy Biomanufacturing Market
- 9.2.1. U.K. Cell Therapy Biomanufacturing Market
- 9.2.2. Germany Cell Therapy Biomanufacturing Market
- 9.2.3. France Cell Therapy Biomanufacturing Market
- 9.2.4. Spain Cell Therapy Biomanufacturing Market
- 9.2.5. Italy Cell Therapy Biomanufacturing Market
- 9.2.6. Rest of Europe Cell Therapy Biomanufacturing Market
9.3. Asia-Pacific Cell Therapy Biomanufacturing Market
- 9.3.1. China Cell Therapy Biomanufacturing Market
- 9.3.2. India Cell Therapy Biomanufacturing Market
- 9.3.3. Japan Cell Therapy Biomanufacturing Market
- 9.3.4. Australia Cell Therapy Biomanufacturing Market
- 9.3.5. South Korea Cell Therapy Biomanufacturing Market
- 9.3.6. Rest of Asia Pacific Cell Therapy Biomanufacturing Market
9.4. Latin America Cell Therapy Biomanufacturing Market
- 9.4.1. Brazil Cell Therapy Biomanufacturing Market
- 9.4.2. Mexico Cell Therapy Biomanufacturing Market
- 9.4.3. Rest of Latin America Cell Therapy Biomanufacturing Market
9.5. Middle East & Africa Cell Therapy Biomanufacturing Market
- 9.5.1. Saudi Arabia Cell Therapy Biomanufacturing Market
- 9.5.2. South Africa Cell Therapy Biomanufacturing Market
- 9.5.3. Rest of Middle East & Africa Cell Therapy Biomanufacturing Market

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. MaxCyte (US)
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. Thermo Fisher Scientific Inc. (US)
- 10.3.3. L7 Informatics, Inc. (US)
- 10.3.4. MAK-SYSTEM (US)
- 10.3.5. SIRION Biotech GmbH (Germany)
- 10.3.6. Fresenius Medical Care AG & Co. KGaA (Germany)
- 10.3.7. Sartorius AG (Germany)
- 10.3.8. STEMCELL Technologies (Canada)
- 10.3.9. Werum IT Solutions GmbH (Germany)
- 10.3.10. Terumo BCT (US)
- 10.3.11. Corning Incorporated (US)
- 10.3.12. OrganaBio, LLC (US)
- 10.3.13. Merck KGaA (Germany)
- 10.3.14. Becton, Dickinson and Company (US)
- 10.3.15. Miltenyi Biotec GmbH (Germany)

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes